Biotech Values

[DewDiligence]

ALVR IPOs 18.7M* shares @$17.00:

https://www.globenewswire.com/news-release/2020/07/30/2070268/0/en/AlloVir-Announces-Pricing-of-Upsized-Initial-Public-Offering.html

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases.

AlloVir is a pretty good name for a company developing allogeneic therapies for viral diseases.

*Assuming exercise of underwriter’s option.